• Home
  • Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting.

Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting.

Author List
Javid J. Moslehi, Mandar A. Aras, Vivian G. Oehler, James E. Thompson, James K. McCloskey, Michael C. Heinrich, Irene S. DeGutis, Susan Meredith Fish, Michael J. Mauro
Publication
Journal of Clinical Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/420600950
Publication Year
2023
Publication Title
Javid J. Moslehi, Mandar A. Aras, Vivian G. Oehler, James E. Thompson, James K. McCloskey, Michael C. Heinrich, Irene S. DeGutis, Susan Meredith Fish, Michael J. Mauro. Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting. Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):7053-7053.